Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mineralized plasmatic matrix (MPM) is a bioactive, autologous-derived grafting complex used in oral and maxillofacial surgery for bone regeneration and ridge preservation. It is prepared by mixing a bone substitute—which may be autogenous bone particles, allograft, xenograft, or synthetic materials like β-tricalcium phosphate—with autologous liquid platelet concentrates (such as liquid platelet-rich fibrin or concentrated growth factors). This process creates a "sticky bone" material where bone particles are immobilized within a cross-linked fibrin network. MPM acts as an osteoconductive scaffold that also provides a concentrated reservoir of regenerative proteins and cytokines, including platelet-derived growth factor (PDGF), transforming growth factor-beta (TGF-β), and vascular endothelial growth factor (VEGF). Clinically, MPM offers superior handling and positional stability compared to particulate grafts alone, facilitating site-specific augmentation in procedures such as sinus lifts, alveolar cleft repairs, and socket preservation by promoting accelerated osteogenesis and soft tissue healing.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mineralized plasmatic matrix.